Biotech RadarJobs updated

COMPANY

Telios Pharma

HQ: Redwood City, CA source · teliospharma.com ↗ · West Coast

Clinical Phase 2

Location: Redwood City, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Allergic Conjunctivitis Dry Eye Disease Myelofibrosis Indolent Systemic Mastocytosis Relapsed/Refractory B Cell Malignancies Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma Treatment-Naive B Cell Malignancies Primary Myelofibrosis Post-PV MF Post-ET Myelofibrosis Acute Myeloid Leukemia COVID-19 Sars-CoV2 Blood Cancer TL-925 TL-895 KRT-232

11Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: Evaluation of TL-925 for the Treatment of Seasonal Allergic Conjunctivitis source ↗
  2. Trial start Phase 2: Evaluation of TL-925 for the Treatment of Allergic Conjunctivitis source ↗
  3. Trial start Phase 2: A Study Of TL-925 For The Treatment of AC source ↗
  4. Trial start Phase 2: A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye Disease source ↗
  5. Trial start Phase 2: A Study of TL-925 for the Treatment of Allergic Conjunctivitis source ↗
  6. Trial start Phase 2: A Study of TL-925 as a Treatment for Dry Eye Disease source ↗
  7. Trial start Phase 1/Phase 2: Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib source ↗
  8. Trial start Phase 1/Phase 2: TL-895 and KRT-232 Study in Acute Myeloid Leukemia source ↗
  9. Trial start Phase 2: Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis source ↗
  10. Trial start Phase 1: A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer source ↗
  11. Trial start I: Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects source ↗

Clinical trials (lead sponsor) 11

RecordTitlePhaseStatusStartPrimary completion
NCT07220408Evaluation of TL-925 for the Treatment of Seasonal Allergic ConjunctivitisPhase 2RecruitingOct 23, 20252026-02 (estimated)
NCT06686472Evaluation of TL-925 for the Treatment of Allergic ConjunctivitisPhase 2RecruitingOct 3, 2024Dec 10, 2024 (estimated)
NCT06225973A Study of TL-925 Ophthalmic Emulsion as a Treatment for Dry Eye DiseasePhase 2Unknown status (ClinicalTrials.gov)Feb 6, 20242024-12 (estimated)
NCT06293820A Study Of TL-925 For The Treatment of ACPhase 2CompletedApr 11, 2024May 21, 2024 (actual)
NCT04655118Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic MastocytosisPhase 2Unknown status (ClinicalTrials.gov)Oct 22, 2020Jun 30, 2025 (estimated)
NCT06153342A Study of TL-925 for the Treatment of Allergic ConjunctivitisPhase 2Unknown status (ClinicalTrials.gov)2023-112024-01 (estimated)
NCT05745064A Study of TL-925 as a Treatment for Dry Eye DiseasePhase 2CompletedFeb 27, 2023Jul 11, 2023 (actual)
NCT02825836Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL SubjectsIUnknown status (ClinicalTrials.gov)Aug 26, 2016Dec 1, 2024 (estimated)
NCT05280509Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to RuxolitinibPhase 1/Phase 2RecruitingJun 9, 20222025-10 (estimated)
NCT04669067TL-895 and KRT-232 Study in Acute Myeloid LeukemiaPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Mar 31, 20212024-11 (estimated)
NCT04419623A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With CancerPhase 1CompletedJul 9, 2020Sep 22, 2020 (actual)
Feedback